HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Annovis Bio (NYSE:ANVS) and maintained a $30 price target, as stated by analyst Raghuram Selvaraju.
July 17, 2024 | 10:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Annovis Bio (NYSE:ANVS) and maintained a $30 price target, indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a $30 price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. It suggests that the firm has confidence in Annovis Bio's future performance, which could lead to increased investor interest and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100